Drug targets and resistance mechanisms in multiple myeloma

Abstract

Multiple myeloma (MM), a malignancy of plasma cells, is the second most prevalent blood cancer (10%). A PubMed search has been conducted for English research papers and reviews published until January 2018. Numerous drugs are used in treatment of MM. These include the antineoplastic alkylating agents cyclophosphamide, busulfan and melphalan, immunomodulators such as lenalidomide and thalidomide, corticosteroids including dexamethasone, microtubule-targeting agents, such as paclitaxel and vinca alkaloids, as well as the proteasome inhibitors bortezomib and carfilzomib. Despite the considerable number of treatment options, MM is still difficult to treat, which is mirrored by the poor 10-year survival rate of 3%. Resistance to chemotherapy is often the cause for therapy failure. These resistances can be due to the overexpression of efflux pumps, genetic and epigenetic aberrations and the microenvironment of MM. With the gain of knowledge regarding genetic and molecular changes, many molecular targeted therapies including cell signaling targeted therapies are being developed against relapsed/refractory MM. Additionally, epigenetic aberrations such as DNA methylation and histone modifications steered MM management in new directions. Amongst these novel targeted therapies, inhibitors of histone deacetylase, Aurora kinase, inhibitors of the PI3K/AKT/mTOR pathway and cyclin dependent kinases are promising.

Keywords

Cancer / drug resistance / drug targets / chemotherapy / genetics / immunotherapy

References

[1] Leng Y,Jin J,Ke X,Pan L,Zhou F,Wang Z,Li W,Qiu L,Li J,Pang H,Wei P,Liu Y,Yang S.Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study..Cancer Chemother Pharmacol2017;79:1141-9

[2] Krishnan SR,Brown RD,Bebawy M.Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)..Int J Oncol2016;49:33-50

[3] Iida S.Mechanisms of action and resistance for multiple myeloma novel drug treatments..Int J Hematol2016;104:271-2

[4] Brenner H,Pulte D.Recent major improvement in long-term survival of younger patients with multiple myeloma..Blood2008;111:2521-6

[5] Palumbo A.Multiple myeloma..N Engl J Med2011;364:1046-60

[6] Krishna R.Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs..Eur J Pharm Sci2000;11:265-83

[7] Almond JB.The proteasome: a novel target for cancer chemotherapy..Leukemia2002;16:433-43

[8] Komander D,Urbe S.Breaking the chains: structure and function of the deubiquitinases..Nat Rev Mol Cell Biol2009;10:550-63

[9] Reits E,Neijssen J,Jalink K,Janssen H,Drijfhout JW.Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I..Immunity2003;18:97-108

[10] Rock KL,Saric T.Protein degradation and the generation of MHC class I-presented peptides..Adv Immunol2002;80:1-70

[11] Obeng EA,Gutman DM,Lee KP.Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells..Blood2006;107:4907-16 PMCID:PMC1895817

[12] Kuhn DJ.The immunoproteasome as a target in hematologic malignancies..Semin Hematol2012;49:258-62 PMCID:PMC3863635

[13] Ettari R,Grasso S,Innao V.Immunoproteasome-selective and non-selective inhibitors: a promising approach for the treatment of multiple myeloma..Pharmacol Ther2018;182:176-92

[14] Accardi F,Bolzoni M,Aversa F.Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling..Biomed Res Int2015;2015:172458 PMCID:PMC4633537

[15] Avet-Loiseau H,Chng WJ,Viterbo L,Ganly P,Cavo M,Pluta A,Kumar S,Rajkumar SV,Berg D,van de Velde H,di Bacco A,Richardson PG.Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients..Blood2017;130:2610-8

[16] Eek D,Mazar I,Pompilus F,Shields AL.Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature..Patient Prefer Adherence2016;10:1609-21 PMCID:PMC5003561

[17] Infante JR,Burris HA3rd,Tolcher AW,Gillenwater HH,Wong HL.A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors..Invest New Drugs2016;34:216-24

[18] Spencer A,Zonder J,Laubach J,Khot A,Chauhan D,MacLaren A,Trikha M.A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results..Br J Haematol2018;180:41-51

[19] Levin N,Harrison SJ,Burrows FJ,Reich SD,Trikha M.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients..Br J Haematol2016;174:711-20 PMCID:PMC5084787

[20] Harrison SJ,Price T,Padrik P,Cannell PK,Trikha M.Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results..Clin Cancer Res2016;22:4559-66

[21] Gandolfi S,Hideshima T,Anderson KC.The proteasome and proteasome inhibitors in multiple myeloma..Cancer Metastasis Rev2017;36:561-84

[22] Shi Y,Hu L,Bookstein R,Lichtenstein A.Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779..Cancer Res2002;62:5027-34

[23] Hideshima T,Richardson P.Identification and validation of novel therapeutic targets for multiple myeloma..J Clin Oncol2005;23:6345-50

[24] Azab F,Abraham J,Muz B,Fiala M,Sultana Z,Abbasi T,Azab AK.PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance..Br J Haematol2014;165:89-101

[25] Gera J.The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma..Leuk Lymphoma2011;52:1857-66

[26] Balsat M.m-TOR inhibitors: biology and use in the treatment of haematological diseases..Bull Cancer2011;98:935-43

[27] Hofmeister CC,Pichiorri F,Rozewski DM,Lee S,Garr CL,Ji J,Benson DMJr,Hicks WJ,Chen CS,Grever MR,Phelps MA.Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein..J Clin Oncol2011;29:3427-34 PMCID:PMC3164245

[28] Yee AJ,Marcheselli R,Cirstea DD,Burke JN,Hideshima T,Ghobrial IM,Munshi NC,Weller EA,Raje NS.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide..Br J Haematol2014;166:401-9

[29] Spencer A,Harrison SJ,Smith DA,Gauvin J,Opalinska JB.The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma..Blood2014;124:2190-5 PMCID:PMC4229853

[30] Tolcher AW,Papadopoulos KP,Becerra CR,Orford K,Ferron-Brady G,Gauvin J,Cornfeld M.Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma..Cancer Chemother Pharmacol2015;75:183-9

[31] Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma. In: U.S. National Library of Medicine; 2018. ClinicalTrials.gov Identifier: NCT01989598.

[32] Clinical Trials Using Akt inhibitor AZD5363. Available from: https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/akt-inhibitor-azd5363 [Last accessed on 14 May 2018]

[33] Oral ONC201 in Relapsed/Refractory Multiple Myeloma. In: U.S. National Library of Medicine; 2018. ClinicalTrials.gov Identifier: NCT02863991.

[34] Richardson PG,Jakubowiak A,Lonial S,Densmore J,Raje N,Martin T,Ghobrial IM,Laubach J,Hideshima T,Poradosu E,Sportelli P.Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial..J Clin Oncol2011;29:4243-9

[35] Earwaker P,Willenbrock F,Protheroe AS.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition..PLoS One2018;13:e0191890 PMCID:PMC5794101

[36] Xu J,Endris V,Md Hanafiah NH,Penzel R,Ho AD,Goldschmidt H,Raab MS.Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation..Oncogenesis2017;6:e337 PMCID:PMC5523069

[37] Chng WJ,Price-Troska T,Rajkumar SV,Kyle RA,Van Wier S,Van Ness B.Clinical and biological significance of RAS mutations in multiple myeloma..Leukemia2008;22:2280-4 PMCID:PMC3864109

[38] Bisping G,Kropff M,Muller-Tidow C,Munzert G,Roth GJ,Volpert S,Berdel WE.Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma..Clin Cancer Res2009;15:520-31

[39] Ramakrishnan V,Haug JL,Wellik LE,Rajkumar SV,Kumar S.Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs..Oncogene2010;29:1190-202 PMCID:PMC2908017

[40] Ramakrishnan V,Haug JL,Halling T,Witzig TE,Adjei AA.Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin..Am J Hematol2012;87:277-83 PMCID:PMC3465673

[41] Srkalovic G,Hoering A,Popplewell LL,Mazzoni S,Orlowski RZ.A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434..Cancer Med2014;3:1275-83 PMCID:PMC4302677

[42] Kumar SK,Marks R,Quevedo F,Croghan G,Bible KC,Tan A,Kaufmann SH,Adjei AA.Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies..Invest New Drugs2013;31:1201-6 PMCID:PMC3779429

[43] Tai YT,Hideshima T,Leiba M,Rumizen M,Morrison A,Chauhan D,Richardson P,Ghobrial IM.Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis..Blood2007;110:1656-63 PMCID:PMC1975848

[44] Ocio EM,San-Segundo L,Corchete LA,Garayoa M,Garcia-Gomez A,Montero JC,Mateos MV,Couto S,Bjorklund CC.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone..Leukemia2015;29:705-14

[45] Holkova B,Kmieciak M,Badros AZ,Baz R,Lin HY,Herrmann M,Raffeld M,Wan W,Shrader E,Sankala H,Doyle A,Wellons M,Sullivan D,Grant S.A phase II trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma..Clin Cancer Res2016;22:1067-75 PMCID:PMC4775365

[46] Rawlings JS,Harrison DA.The JAK/STAT signaling pathway..J Cell Sci2004;117:1281-3

[47] Beldi-Ferchiou A,Ben Ali C,Abdelkefi A,Mrad K,Ben Ahmed M.Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma..PLoS One2017;12:e0174835 PMCID:PMC5378363

[48] Ramakrishnan V,Haug J,Wellik L,Pardanani A,Rajkumar SV.TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells..Am J Hematol2010;85:675-86 PMCID:PMC2940994

[49] de Oliveira MB,Eugenio AIP,Sanson LFG,Braga WMT,Colleoni GWB.Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: a rationale for JAK/STAT pathway inhibition in myeloma patients..Cancer Lett2017;403:206-15

[50] Sagawa M,Kimura Y,Nemoto-Anan T,Tokuhira M,Hashimoto Y,Kizaki M.TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities..Cancer Sci2015;106:438-46 PMCID:PMC4409888

[51] Sagawa M,Uchida H,Kizaki M.Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway..Cancer Sci2008;99:1820-6

[52] Nakaya A,Muto A,Ikeda Y.The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity..Leuk Res2011;35:243-9

[53] Le Gouill S,Harousseau JL,Robillard N,Amiot M.Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells..Leukemia2002;16:1664-7

[54] Li J,Kelley JA,Thomas B,Sparks RB,Rogers JD,Vaddi K,Scherle PA,Fridman JS.INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support..Neoplasia2010;12:28-38 PMCID:PMC2805881

[55] Jin Z,Zhang Y,Jiang S,Ma Y.Lycorine induces cell death in MM by suppressing Janus kinase/signal transducer and activator of transcription via inducing the expression of SOCS1..Biomed Pharmacother2016;84:1645-53

[56] Pedranzini L,Berishaj M,Zhou P,Bornmann W.Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells..Cancer Res2006;66:9714-21

[57] Amit-Vazina M,Harris D,Wang M,Alexanian R,Aggarwal BB.Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells..Br J Cancer2005;93:70-80 PMCID:PMC2361492

[58] Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma. In: U.S. National Library of Medicine; 2018. ClinicalTrials.gov Identifier: NCT00086216.

[59] Kampan NC,McNally OM,Quinn MA.Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities..Curr Med Chem2017;doi: 10.2174/0929867324666170712160621

[60] Orlowski RZ,Williams C,Robak T,Goranova-Marinova V,Cavenagh JD,Maiolino A,Blade J,Puchalski TA,Bandekar R,Xie H.A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma..Am J Hematol2015;90:42-9 PMCID:PMC4737504

[61] San-Miguel J,Shpilberg O,Maloisel F,Polo Zarzuela M,Prasad SV,Laubach J,Mateos MV,Puchalski T,Uhlar C,van de Velde H,Orlowski RZ.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma..Blood2014;123:4136-42 PMCID:PMC4123433

[62] Follin-Arbelet V,Naderi EH,Sundan A.Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway..Cancer Lett2013;335:323-31

[63] Ko JH,Nam D,Lee SG,Mo Yang W,Seok Ahn K.3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3..Immunopharmacol Immunotoxicol2016;38:334-43

[64] Monaghan KA,Burns CJ.The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells..Leukemia2011;25:1891-9

[65] Che Y,Kang Z.Serenoa repens induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 signaling..Oncol Rep2009;22:377-83

[66] Pandey MK,Ahn KS.Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1..Mol Pharmacol2009;75:525-33 PMCID:PMC2684906

[67] Nelson EA,Kepich A,Hideshima T,Chauhan D,Frank DA.Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3..Blood2008;112:5095-102 PMCID:PMC2597607

[68] De Vos J,Tarte K,Klein B.JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells..Br J Haematol2000;109:823-8

[69] Komiya Y.Wnt signal transduction pathways..Organogenesis2008;4:68-75 PMCID:PMC2634250

[70] Grainger S,Willert K.Wnt signaling in hematological malignancies..Prog Mol Biol Transl Sci2018;153:321-41

[71] Cheng Q,Fu Y,Yang Y.RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signalling pathway..Clin Exp Pharmacol Physiol2018;45:140-5

[72] Wang JH,Li HY,Sun T.Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions..Medicine (Baltimore).2016;95:e3767 PMCID:PMC4998439

[73] Zhou F,Song H.Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention..Blood Rev2013;27:261-7 PMCID:PMC4133945

[74] Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma. In: U.S. National Library of Medicine; 2018. ClinicalTrials.gov Identifier: NCT01302886.

[75] Terpos E,Gavriatopoulou M.Mechanisms of bone destruction in multiple myeloma..Eur J Cancer Care (Engl).2017;26:12761

[76] McDonald MM,Youlten SE,Seckinger A,Pettitt JA,Cheng TL,Le LMT,Kramer I,Fairfield H,Baldock PA,Kneissel M,Bassett JHD,Oyajobi BO,Phan TG.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma..Blood2017;129:3452-64 PMCID:PMC5492093

[77] Bjorklund CC,Wang ZQ,Kuhn DJ,Wang M,Orlowski RZ.Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide..J Biol Chem2011;286:11009-20 PMCID:PMC3064156

[78] Butrym A,Lacina P,Frontkiewicz D,Mazur G.Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment..Leuk Res2015;39:1462-6

[79] Demchenko YN.A critical role for the NFkB pathway in multiple myeloma..Oncotarget2010;1:59-68 PMCID:PMC2947827

[80] Chim CS.Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients..J Transl Med2010;8:124 PMCID:PMC3003638

[81] Chng WJ,Vanwier S,Price-Troska T,Chung TH,Mulligan G,Carpten J,Rajkumar SV,Dispenzieri A,Greipp P,Fonseca R.Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling..Cancer Res2007;67:2982-9

[82] Keats JJ,Chesi M,Baker A,Van Wier S,Shi CX,Braggio E,Zhu YX,Price-Troska T,Mancini C,Kumar S,Dispenzieri A,Mulligan G,Barrett M,Trent J,Carpten J.Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma..Cancer Cell2007;12:131-44 PMCID:PMC2083698

[83] Bolzoni M,Storti P,Costa F.Possible targets to treat myeloma-related osteoclastogenesis..Expert Rev Hematol2018;11:325-36

[84] Terpos E,Christoulas D,Katodritou E.RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases..Expert Opin Biol Ther2009;9:465-79

[85] Raje N,Willenbacher W,Hungria V,Alexeeva Y,Stewart AK,Braun A,Roodman GD.Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial..Blood Cancer J2016;6:e378 PMCID:PMC4742634

[86] Body JJ,Coleman RE,Geurs F,Harousseau JL,Mariette X,Nakanishi A,Martin SW,Bekker PJ.A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases..Cancer2003;97:887-92

[87] Terpos E,Szydlo R,Karkantaris C,Voskaridou E,Dimopoulos MA.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio..Leukemia2005;19:1969-76

[88] Tsubaki M,Yoshizumi M,Itoh T,Satou T.RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines..Tumour Biol2016;37:9099-110

[89] Santo L,Raje N.Targeting cyclin-dependent kinases and cell cycle progression in human cancers..Semin Oncol2015;42:788-800

[90] Casimiro MC,Aguirre-Alvarado C.Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present..Expert Opin Investig Drugs2014;23:295-304

[91] Ramakrishnan VG.Inhibitors of the cyclin-dependent kinase and PIM kinase pathways in the treatment of myeloma..Cancer J2016;22:7-11

[92] MacCallum DE,Frame S,Anderson S,Lane DP.Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1..Cancer Res2005;65:5399-407

[93] Hofmeister CC,Bowers MA,Phelps MA,Kraut EH,Efebera YA,Lin TS,Byrd JC.A phase I trial of flavopiridol in relapsed multiple myeloma..Cancer Chemother Pharmacol2014;73:249-57 PMCID:PMC3946636

[94] Holkova B,Ramakrishnan V,Shrader E,Wellons MD,Roodman GD,Kang L,Stuart RK,Figg WDSr,Doyle A,Sullivan DM,Grant S.Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms..Clin Cancer Res2011;17:3388-97 PMCID:PMC3096752

[95] Fandy TE,Gore SD.Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL..Cancer Chemother Pharmacol2007;60:313-9

[96] Pei XY,Grant S.The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism..Mol Cancer Ther2004;3:1513-24

[97] Niesvizky R,Costa LJ,Singhal SB,Haideri NA,Hess G,Spicka I,Raab MS,Vij R,Huang X,Di Liberto M,Jiang Y,Randolph S.Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma..Leuk Lymphoma2015;56:3320-8

[98] Kumar SK,Chng WJ,Callander N,Fruth B,Erlichman C,Mayo Phase 2 Consortium.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma..Blood2015;125:443-8 PMCID:PMC4296007

[99] Feng R,Lu C,Stolz DB,Lentzsch S.Targeting the microtubular network as a new antimyeloma strategy..Mol Cancer Ther2011;10:1886-96

[100] Maes A,Veirman K,Vand Erkerken K.The therapeutic potential of cell cycle targeting in multiple myeloma..Oncotarget2017;8:90501-20 PMCID:PMC5685770

[101] Kyle RA,Friedenberg WR,Rajkumar SV.The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93..Cancer2009;115:2155-64 PMCID:PMC4066392

[102] Dimopoulos MA,Huber M,Luckett R,Alexanian R.Primary therapy of multiple myeloma with paclitaxel (taxol)..Ann Oncol1994;5:757-9

[103] Miller HJ,Khandekar JD,Gertz MA.Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93)..Am J Clin Oncol1998;21:553-6

[104] Kawano T,Kharbanda S,Kufe D.A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells..Cancer Chemother Pharmacol2007;59:329-35

[105] Maginn EN,Hayden P,MacDonagh B,Goodyer M,Campiani G,Williams DC,Lawler MP.PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells..Br J Cancer2011;104:281-9 PMCID:PMC3031893

[106] Spagnuolo PA,Hurren R,Gronda M,Di Meo A,Ashali I,Fine N,Sharmeen S,Schimmer AD.The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma..Blood2010;115:4824-33

[107] Pandey MK,Sung SS,Budak-Alpdogan T,Dovat S.A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis..Exp Hematol2017;53:31-42

[108] Rozic G,Jakubikova J,Duek A,Avigdor A,Leiba M.The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo..Oncotarget2016;7:62572-84 PMCID:PMC5308747

[109] Liu M,Liu C,Gao J,Dong JT,Giannis A,Zhou J.Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells..J Biol Chem2006;281:18090-7

[110] Hernandez-Garcia S,Gonzalez-Mendez L,Misiewicz-Krzeminska I,Lopez-Iglesias AA,Mogollon P,Paino T,Mateos MV,Diaz-Rodriguez E,Ocio EM.The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma..Haematologica2017;102:2113-24 PMCID:PMC5709111

[111] Shah JJ,Zonder JA,Bensinger WI,Rush SA,Tunquist BJ,Ptaszynski M,Lonial S.A phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma..Cancer2017;123:4617-30

[112] Chari A,Zonder JA,Jakubowiak AJ,Lau K,Tunquist BJ,Rush SA,Ptaszynski M.A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma..Cancer2016;122:3327-35

[113] Song IS,Nyamaa B,Kim HK,Ko KS,Han J.KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-kappaB signaling pathway..BMB Rep2015;48:571-6 PMCID:PMC4911184

[114] Tang A,Chu L,Yang J.Aurora kinases: novel therapy targets in cancers..Oncotarget2017;8:23937-54

[115] Shi Y,Li W,Sen S,Daniels TR,Feldman R.Targeting aurora kinases as therapy in multiple myeloma..Blood2007;109:3915-21 PMCID:PMC1874561

[116] Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma. In: U.S. National Institutes of Health; 2018. ClinicalTrials.gov Identifier: NCT01034553.

[117] Hay AE,DiPasquale AM,Sandhu I,Bahlis NJ,Reece DE,Sederias J,Powers J,Reiman T.A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191..Leuk Lymphoma2016;57:1463-6

[118] Abdi J,Li L,Chang H.Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis..J Hematol Oncol2017;10:169 PMCID:PMC5659022

[119] Hientz K,Bhakta-Guha D.The role of p53 in cancer drug resistance and targeted chemotherapy..Oncotarget2017;8:8921-46 PMCID:PMC5352454

[120] Gillardin PS,Maiga S,Djamai H,Chiron D,Le Gouill S,Pellat-Deceunynck C.Decitabine and melphalan fail to reactivate p73 in p53 deficient myeloma cells..Int J Mol Sci2017;19:E40 PMCID:PMC5795990

[121] Hideshima T,Nozawa Y,Ohguchi H,Cirstea D,Iwasawa Y,Munshi NC,Massefski W,Dhe-Paganon S.p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma..Blood2017;129:1308-19 PMCID:PMC5345734

[122] Liu N,Wu N.Acetylation and deacetylation in cancer stem-like cells..Oncotarget2017;8:89315-25

[123] Mihaila RG.From a better understanding of the mechanisms of action of histone deacetylases inhibitors to the progress of the treatment of malignant lymphomas and plasma cell myeloma..Recent Pat Anticancer Drug Discov2017;12:283-95

[124] Raedler LA.Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma..Am Health Drug Benefits2016;9:84-7 PMCID:PMC5013857

[125] Badros A,Philip S,Kolla SS,Harris C,Wright JJ,Baer MR,Egorin MJ.Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma..Clin Cancer Res2009;15:5250-7 PMCID:PMC2758911

[126] Deming DA,Bailey HH,Eickhoff J,Ames MM,Alberti D,Espinoza-Delgado I,Wilding G.A phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors..Invest New Drugs2014;32:323-9 PMCID:PMC3949160

[127] Cho H,Kim KP,Kim WS,Kim JS,Kim SJ,Kim SJ.Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy..Invest New Drugs2018;doi: 10.1007/s10637-018-0582-0.

[128] Klappe K,Kroesen BJ,Kok JW.MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells..Int J Cancer2004;110:511-22

[129] Furukawa Y.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma..Int J Hematol2016;104:281-92

[130] Raaijmakers MH.ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia..Leukemia2007;21:2094-102

[131] Aller SG,Ward A,Chittaboina S,Harrell PM,Zhang Q,Chang G.Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding..Science2009;323:1718-22 PMCID:PMC2720052

[132] Ward A,Yu J,Chang G.Flexibility in the ABC transporter MsbA: alternating access with a twist..Proc Natl Acad Sci U S A2007;104:19005-10 PMCID:PMC2141898

[133] Ferreira RJ,Dos Santos DJ.Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations..J Chem Theory Comput2012;8:1853-64

[134] Abraham J,Azab AK.The role of P-glycoprotein in drug resistance in multiple myeloma..Leuk Lymphoma2015;56:26-33

[135] Verbrugge SE,Dijkmans BA,Al M,Oerlemans R,Kirk CJ,van der Heijden JW,Scheper RJ.Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis..J Pharmacol Exp Ther2012;341:174-82

[136] O'Connor R,Meiller J,Klippel S,Richardson P,Clynes M,O'Gorman P.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias..Cancer Chemother Pharmacol2013;71:1357-68 PMCID:PMC4414393

[137] Dalton WS,Meltzer PS,Durie BG,Miller TP.Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy..J Clin Oncol1989;7:415-24

[138] Grogan T,Rybski J,Meltzer P,Gleason M,Cline A.Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies..Lab Invest1990;63:815-24

[139] Fonti R,Zannetti A,Catalano L,Rotoli B.Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma..Cancer Biother Radiopharm2004;19:165-70

[140] Fallahi B,Mousavi SA,Eftekhari M,Alimoghaddam K,Eskandarian A.99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients..Hell J Nucl Med2009;12:255-9

[141] Marie JP.P-glycoprotein in adult hematologic malignancies..Hematol Oncol Clin North Am1995;9:239-49

[142] Turner JG,Zhang C,Marchion D,Munster P,Dalton WS.ABCG2 expression, function, and promoter methylation in human multiple myeloma..Blood2006;108:3881-9 PMCID:PMC1895461

[143] Advani AS,Ali-Osman F,Rybicki L,Sekeres MA,Diehl LF,Beaven A,Sobecks R,Rizzieri DA.A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse..Clin Lymphoma Myeloma Leuk2010;10:473-6

[144] Yin G,Ni Y,Wu H,Qian S,Li J,Miao K.Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population..Tumour Biol2016;37:9549-54

[145] Martino A,Buda G,Garcia-Sanz R,Reis RM,Jurado M,Szemraj-Rogucka Z,Szemraj J,Kumar R,Gemignani F,Goldschmidt H,Dumontet C,Rossi AM.Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium..Leukemia2012;26:1419-22

[146] Drain S,Bjourson AJ,Kettle PJ.Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma..Cytometry B Clin Cytom2012;82:229-37

[147] Schaich M,Thiede C,Illmer T.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia..Br J Haematol2005;128:324-32

[148] Ao L,Kim D,Kim K,Kim KB.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib..Mol Pharm2012;9:2197-205 PMCID:PMC3473138

[149] Lilienbaum A.Relationship between the proteasomal system and autophagy..Int J Biochem Mol Biol2013;4:1-26 PMCID:PMC3627065

[150] White E.The double-edged sword of autophagy modulation in cancer..Clin Cancer Res2009;15:5308-16 PMCID:PMC2737083

[151] Milani M,Mellor HR,Bottini A,Harris AL.The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib..Cancer Res2009;69:4415-23

[152] Ding WX,Gao W,Kang JH,Liu J.Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy..Mol Cancer Ther2009;8:2036-45 PMCID:PMC2711219

[153] Yoshida GJ.Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment..J Hematol Oncol2017;10:67 PMCID:PMC5345270

[154] Podar K,Zhang J,Breitkreutz I,Lin BK,Hideshima T,Anderson KC.Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)..Blood2007;109:1669-77 PMCID:PMC1794057

[155] Raab MS,Tonon G,Hayden PJ,Fruehauf JH,Chauhan D,Munshi NC,Podar K.Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling..Blood2009;113:1513-21 PMCID:PMC2644079

[156] Yang Y,Saha MN,Evans K,Reece D,Chang H.Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma..Leukemia2015;29:715-26

[157] Bonnet D.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell..Nat Med1997;3:730-7

[158] Franqui-Machin R,Janz S,Tricot G.Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?.Oncotarget2015;6:40496-506 PMCID:PMC4747348

[159] Hu JS,Huang YD,Lu QY.Effect of Hedgehog signaling pathway abnormality on chemothe-rapeutic resistance of multiple myeloma..Zhongguo Shi Yan Xue Ye Xue Za Zhi2017;25:465-70(in Chinese)

[160] Zhao JJ,Zhu D,Brooks D,Chu ZB,Ciccarelli B,Tao J,Treon S,Kuo WP,Bouxsein M,Anderson K.miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway..Cancer Res2014;74:1801-13 PMCID:PMC3959627

[161] Tang B,Xu J,Chen L,Zhang L,Fan F,Tang L,Hu Y.MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling..Int J Cancer2018;142:109-20

[162] Xu Z,Hao D.MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway..Oncol Rep2017;37:1261-9

[163] Yang Y,Tolomelli G,Xia J,Zhou W,Das S,Levasseur D,Tricot G.RARalpha2 expression confers myeloma stem cell features..Blood2013;122:1437-47 PMCID:PMC3750340

[164] Cheng T,Shen H,Dombkowski D,Scadden DT.Hematopoietic stem cell quiescence maintained by p21cip1/waf1..Science2000;287:1804-8

[165] Januchowski R,Zabel M.The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance..Biomed Pharmacother2013;67:669-80

[166] Saltarella I,Reale A,Ria R.Identify multiple myeloma stem cells: Utopia?.World J Stem Cells2015;7:84-95 PMCID:PMC4300939

[167] Mirandola L,Colombo M,Berta DG,Lazzari E,Bulfamante G,Chiriva-Internati M.Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1..Leukemia2013;27:1558-66

[168] Podar K,Davies FE,Sattler M,Lin BK,Shima Y,Mitsiades C,Richardson P.Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration..Blood2001;98:428-35

[169] Meads MB,Dalton WS.The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance..Clin Cancer Res2008;14:2519-26

[170] Bianchi G,Ghobrial IM.Cell trafficking in multiple myeloma..Open J Hematol2012;3:4 PMCID:PMC3677225

[171] Bar-Natan M,Luptakova K,Apel A,Pyzer AR,Reagan MR,Karp Leaf R,Arnason J,Anderson KC,Rosenblatt J.Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1..Br J Haematol2017;176:929-38 PMCID:PMC5800979

[172] Kikuchi J,Koyama D,Izumi T,Kawase T,Furukawa Y.Myeloma cells are activated in bone marrow microenvironment by the CD180/MD-1 complex which senses lipopolysaccharide..Cancer Res2018;78:1766-78

[173] Gu C,Lu Y,Tian Z,Zhang W,Zhang Y.BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling..Oncotarget2017;8:56858-67 PMCID:PMC5593608

[174] Yang Y,Gu Z,Das S,Xu H,Tao Y,Franqui R,Janz S,Zhan F.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma..Cancer Res2015;75:594-604 PMCID:PMC4384656

[175] Kobune M,Kato J,Nakamura K,Takada K,Takayama T,Niitsu Y.Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism..Mol Cancer Ther2007;6:1774-84

[176] Di Marzo L,Solimando AG,Annese T,Fumarulo R,Frassanito MA.Microenvironment drug resistance in multiple myeloma: emerging new players..Oncotarget2016;7:60698-711 PMCID:PMC5312413

[177] Caivano A,De Luca L,Simeon V,D'Auria F,Maietti M,D'Arena G,Pietrantuono G,Musto P.High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders..Tumour Biol2015;36:9739-52

[178] Roccaro AM,Maiso P,Tai YT,Azab F,Campigotto F,Anderson KC,Ghobrial IM.BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression..J Clin Invest2013;123:1542-55 PMCID:PMC3613927

[179] Frassanito MA,Moschetta M,Di Marzo L,Racanelli V,Berardi S,Menu E,Nico B,Fumarulo R,Vanderkerken K.Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies..Leukemia2014;28:904-16

[180] Tsuyama N,Abroun S,Li FJ,Zheng X,Taniguchi O.The regulatory mechanism of IL-6-dependent proliferation of human myeloma cells..Hematology2003;8:409-11

[181] Yang H,Xi Y.Effects of survivin on FVADT chemotherapy for refractory multiple myeloma..Exp Ther Med2016;12:771-6 PMCID:PMC4950835

[182] Wagner V,Seckinger A,Meißner T,Rossi JF,Krämer A,Raab MS.Survivin in multiple myeloma: prognostic and therapeutic implications..Blood2011;118:137

[183] Desplanques G,Delsignore R,Bataille R.Impact of XIAP protein levels on the survival of myeloma cells..Haematologica2009;94:87-93 PMCID:PMC2625405

[184] Abe S,Yamamoto K,Nakagawa Y,Takizawa T.Rapid induction of IAP family proteins and Smac/DIABLO expression after proapoptotic stimulation with doxorubicin in RPMI 8226 multiple myeloma cells..Exp Mol Pathol2007;83:405-12

[185] Nakagawa Y,Kurata M,Yamamoto K,Takemura T,Kitagawa M.IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes..Am J Hematol2006;81:824-31

[186] De Veirman K,Lub S,Thielemans K,Oyajobi BO,Menu E,Van Riet I,Van Valckenborgh E.Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells..Oncotarget2015;6:10532-47 PMCID:PMC4496373

[187] Le Gouill S,Amiot M,Chauhan D,Kumar S,Richardson PG,Anderson KC.VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis..Blood2004;104:2886-92

[188] Merz M,Hielscher T,Schonland SO,Hose D,Neben K,Hillengass J,Blau IW,Schmidt-Wolf IGH,Haenel M,Goldschmidt H.Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma..Blood Adv2018;2:1-9 PMCID:PMC5761630

[189] Rasche L,Stephens OW,Tytarenko R,Bauer M,Deshpande S,Buzder T,Zangari M,Thanendrarajan S,Epstein J,Walker BA,Barlogie B,Weinhold N.Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing..Nat Commun2017;8:268 PMCID:PMC5559527

[190] Hebraud B,Lauwers-Cances V,Caillot D,Karlin L,Gentil C,Garderet L,Brechignac S,Jaubert J,Stoppa AM,Fohrer C,Fruchart C,Orsini-Piocelle F,Sohn C,Facon T,Attal M.Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients..Leukemia2014;28:675-9

[191] Gertz MA,Dispenzieri A,Litzow MR,Van Wier SA,Fonseca R.Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy..Blood2005;106:2837-40 PMCID:PMC1895302

[192] Avet-Loiseau H,Magrangeas F,Harousseau JL.Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors..Blood2001;98:3082-6

[193] Bolli N,Wedge DC,Alexandrov LB,Dawson KJ,Nik-Zainal S,Hinton JW,Tubio JM,S OM,Teague JW,Anderson E,Tai YT,Sperling AS,Richardson PG,Magrangeas F,Moreau P,Facon T,Anderson KC,Munshi NC.Heterogeneity of genomic evolution and mutational profiles in multiple myeloma..Nat Commun2014;5:2997 PMCID:PMC3905727

[194] Chapman MA,Keats JJ,Sougnez C,Harview CL,Ahmann GJ,Anderson KC,Auclair D,Bergsagel PL,Drier Y,Gabriel SB,Jagannath S,Krishnan A,Liefeld T,Mahan S,Monti S,Onofrio R,Rajkumar SV,Siegel DS,Stewart AK,Vij R,Winckler W,Carpten J,Hahn WC,Meyerson M,Getz G.Initial genome sequencing and analysis of multiple myeloma..Nature2011;471:467-72 PMCID:PMC3560292

[195] Kortuem KM,Bruins L,Shi CS,Tibes R,Votruba P,Fonseca R,Schlam I,Bergsagel PL.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients..Blood Cancer J2016;6:e397 PMCID:PMC4771964

[196] Johnson DC,Mitchell JS,Kaiser M,Hillengass J,Gregory WA,Jackson GH,Nickel J,Noethen MM,Barlogie B,Hemminki K,Houlston RS.Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma..Nat Commun2016;7:10290 PMCID:PMC4729868

[197] Shah V,Houlston RS.Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report..BMC Cancer2017;17:718 PMCID:PMC5674776

[198] Basmaci C,Tomatir A,Okan V,Oguzkan-Balci S.Effects of TNFalpha, NOS3, MDR1 gene polymorphisms on clinical parameters, prognosis and survival of multiple myeloma cases..Asian Pac J Cancer Prev2016;17:1009-14

[199] Corre J,Avet-Loiseau H.Genetics of multiple myeloma: another heterogeneity level?.Blood2015;125:1870-6 PMCID:PMC4366624

[200] Andrulis M,Capper D,Heining C,Zenz T,Schirmacher P,Goldschmidt H,Raab MS.Targeting the BRAF V600E mutation in multiple myeloma..Cancer Discov2013;3:862-9

[201] Lu S,Chen Z,Zhou H,Wang J.Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line..Exp Hematol2009;37:831-7

[202] Balsas P,Marzo I.Bortezomib resistance in a myeloma cell line is associated to PSMbeta5 overexpression and polyploidy..Leuk Res2012;36:212-8

[203] Niewerth D,Assaraf YG,Kaspers GJ.Molecular basis of resistance to proteasome inhibitors in hematological malignancies..Drug Resist Updat2015;18:18-35

[204] Pichiorri F,Ladetto M,Palumbo T,Taccioli C,Alder H,Munker R,Boccadoro M,Palumbo A,Croce CM.MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis..Proc Natl Acad Sci U S A2008;105:12885-90 PMCID:PMC2529070

[205] Mithraprabhu S,Chow A,Spencer A.Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma..Epigenetics2014;9:1511-20 PMCID:PMC4622977

[206] Abedin SM,Munshi HG.BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects..Onco Targets Ther2016;9:5943-53 PMCID:PMC5047722

[207] Robertson KD.DNA methylation and human disease..Nat Rev Genet2005;6:597-610

[208] Sive JI,Smith D,Beck S.Global hypomethylation in myeloma is associated with poor prognosis..Br J Haematol2016;172:473-5

[209] Zhang W,Zhang Y,Reagan M,Mishima Y,Manier S,Jiang B,Ghobrial IM.Global epigenetic regulation of microRNAs in multiple myeloma..PLoS One2014;9:e110973 PMCID:PMC4201574

[210] Bi C,Huang G,Yan J,Fonseca R.Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma..Oncotarget2015;6:26508-18 PMCID:PMC4694918

[211] Dupere-Richer D.Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma..Curr Opin Hematol2017;24:336-44

[212] Pawlyn C,Heuck C,Wardell CP,Chavan SS,Begum DB,Proszek PZ,Boyle EM,Cook G,Owen RG,Jackson GH,Davies FE,Morgan GJ.The spectrum and clinical impact of epigenetic modifier mutations in myeloma..Clin Cancer Res2016;22:5783-94 PMCID:PMC5124543

[213] Chim CS,Orlowski RZ,Richardson PG,Giralt S,Leleu X.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond..Leukemia2018;32:252-62 PMCID:PMC5808071

[214] Sonneveld P.Treatment of relapsed and refractory multiple myeloma..Haematologica2016;101:396-406 PMCID:PMC5004403

[215] Cornell RF.Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity..Bone Marrow Transplant2016;51:479-91 PMCID:PMC4827007

[216] Dimopoulos M,Stadtmauer EA,Zonder JA,Masliak Z,Olesnyckyj M,Weber DM.The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function..Cancer2010;116:3807-14 PMCID:PMC2970911

[217] Dimopoulos M,Lonial S,Hajek R,Rosinol L,Blacklock H,Hungria V,Palumbo A,Eid JE,Sun L,Anderson KC.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study..Lancet Oncol2013;14:1129-40

[218] Laubach J,Mahindra A,Caers J,Voorhees P,Johnsen HE,Jurczyszyn A,Mellqvist UH,Pilarski L,Hou J,Zamagni E,Mazumder A,Lu J,Kristinsson S,Roussel M,Terpos E,Dimopoulos M,Orlowski RZ,Anderson KC,Kumar S,Durie B.Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group..Leukemia2016;30:1005-17

[219] Matsui W,Mitsiades C.Autologous stem cell transplantation and multiple myeloma cancer stem cells..Biol Blood Marrow Transplant2012;18:S27-32 PMCID:PMC3260462

[220] Byrne M,Leather H,Davis A,Wiggins L,An Q,Moreb JS.Tandem autologous stem cell transplantation for multiple myeloma patients based on response to their first transplant-a prospective phase II study..Clin Med Insights Oncol2014;8:101-5 PMCID:PMC4159376

[221] Cowan AJ,Libby EN,Coffey DG,Hyun TS,Gopal AK.Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy..Biol Blood Marrow Transplant2018;doi: 10.1016/j.bbmt.2018.02.017.

[222] Lee SE,Ryu DB,Jeon YW,Cho BS,Kim YJ,Lee S,Kim DW,Min WS.Circulating CD3(+)CD4(+)CD161(+) cells are associated with early complications after autologous stem cell transplantation in multiple myeloma..Biomed Res Int2018;2018:5097325 PMCID:PMC5817817

[223] Pulte ED,Nie L,McKee AE,Pazdur R.FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma..Oncologist2018;doi: 10.1634/theoncologist.2017-0440.

[224] Micallef IN,Nademanee AP,Horwitz ME,Kaufman JL,Vargo R,Struijs M,DiPersio JF.Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report..Biol Blood Marrow Transplant2018;;

[225] Gossi U,Mansouri Taleghani B,Novak U,Egger T,Pabst T.Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft..Hematol Oncol2018;36:436-44

[226] Sonneveld P,Huisman C,Schoester M,van Kapel J,Charnick S,Lowenberg B.Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study..Leukemia1996;10:1741-50

[227] Dalton WS,Salmon SS,Laufman LR,Bonnet JD.A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study..Cancer1995;75:815-20

[228] Friedenberg WR,Blood EA,Shustik C,Sonneveld P.Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group..Cancer2006;106:830-8

[229] Gulla A,Gallo Cantafio ME,Amodio N,Pitari MR,Britti D,Hideshima T,Anderson KC,Tassone P.A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells..Clin Cancer Res2016;22:1222-33 PMCID:PMC4775414

[230] Jones RJ,Bjorklund CC,Remaley AT,Vreys V.The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1..J Pharmacol Exp Ther2013;346:381-92 PMCID:PMC3876782

[231] Mark E.Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells..Med Chem Commun2016;8:10

[232] Issa ME,Gunatilaka AAL.Withanolide D exhibits similar cytostatic effect in drug-resistant and drug-sensitive multiple myeloma cells..Front Pharmacol2017;8:610 PMCID:PMC5596074

[233] Matsui W,Brennan S,Tressler R,Huff CA,Jones R.The novel telomerase inhibitor GRN163L targets drug-resistant cancer stem cells in multiple myeloma..Mol Cancer Ther2007;6 Suppl 11:A97

[234] Richardson PG,Huff CA,Lendvai N,Anderson LDJr,Lebovic D,Laubach JP,Kwei L,Elias L,Graef T,Vij R.Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results..Br J Haematol2018;180:821-30 PMCID:PMC5873373

[235] Rius M.Epigenetic cancer therapy: rationales, targets and drugs..Oncogene2012;31:4257-65

[236] Amorim S,Gleeson M,Magarotto V,Morschhauser F,Broussais F,Herait P,Lokiec F,Facon T,Cunningham D,Thieblemont C.Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study..Lancet Haematol2016;3:e196-204

[237] Drew AE,Jacques SL,Boriack-Sjodin AP,Scott MP,Raimondi A,Ott HM,McCabe MT,Riera T,Waters NJ,Duncan KW,Copeland RA,Chesworth R.Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma..Sci Rep2017;7:17993 PMCID:PMC5740082

[238] Sonneveld P,Weijermans P,Neuwirtova R,Lokhorst H,Dohner H,Segeren CM,Lowenberg B.Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914)..Br J Haematol2001;115:895-902

[239] Dimopoulos K,Fibiger Munch-Petersen H,Christensen J,Asmar F,O'Connel C,Liang G.Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner..Mol Oncol2018;12:180-95 PMCID:PMC5792743

[240] Alzrigat M,Majumder MM,Jin J,Nahi H,Heckman CA,Kalushkova A.The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains..Oncotarget2017;8:103731-43 PMCID:PMC5732762

[241] Jakubowiak A,Pegourie B,Garderet L,Bosi A,Laubach J,Carella AM,Tsao LC,Bleickardt E,Robbins M.Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM..Blood2016;127:2833-40 PMCID:PMC4900953

[242] Lonial S,Usmani SZ,Chari A,Belch A,Vescio RA,Mazumder A,Sutherland HJ,Scott EC,Berdeja J,Stevens DA,Sebag M,Jakubowiak A,de la Rubia J,Lisby S,Uhlar CM,Ahmadi T.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial..Lancet2016;387:1551-60

[243] Schonfeld K,Pinkas J,Bernoster K.Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies..J Hematol Oncol2017;10:13 PMCID:PMC5225632

[244] Karadimitris A,Caputo V,Ponnusamy K.Myeloma propagating cells, drug resistance and relapse..Stem Cells2015;33:3205-11

[245] Ritchie JP,Ren Y,Torri G,Penco S,Carminati P,Zunino F,Sanderson RD.SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis..Clin Cancer Res2011;17:1382-93 PMCID:PMC3060291

[246] Vasuthasawat A,Trinh KR,Timmerman JM.Targeted immunotherapy using anti-CD138-interferon alpha fusion proteins and bortezomib results in synergistic protection against multiple myeloma..MAbs2016;8:1386-97 PMCID:PMC5058616

[247] Kulkarni U,Kohler T,Bommert K,Meng L,Recke A,Pollok K,Bogen B,Kamradt T,Langer C,Finkelman FD,Wong DM.IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration..J Allergy Clin Immunol2016;137:1487-97.e6

[248] Muthu Raja KR,Zahradova L,Penka M.Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma..PLoS One2012;7:e47077 PMCID:PMC3468567

[249] Comeau JM,Jean GW.The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma..Am J Health Syst Pharm2018;75:55-66

[250] Frerichs KA,Lindenbergh PL,Marin Soto J,Groen RWJ,Nieuwenhuis L,Nijhof IS,Zweegman S,van de Donk N.CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience..Expert Rev Clin Immunol2018;14:197-206

[251] Qin H,Sakamaki I,Cheng WA,Wen F,Kim K,Bover L,Kwak LW.Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug-resistant human B-cell malignancies in vivo..Clin Cancer Res2018;24:1114-23

[252] Yang C,Wang J,Chen J,Zhang Y,Gu N.Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma..Nanomedicine (Lond).2014;9:45-60

[253] Study of Natalizumab in Relapsed/Refractory Multiple Myeloma. In: U.S. National Library of Medicine; 2008. ClinicalTrials.gov Identifier: NCT00675428.

[254] Podar K,Fulciniti M,Hainz U,Vallet S,Jager D,Sattler M,Anderson KC.The selective adhesion molecule inhibitor natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications..Br J Haematol2011;155:438-48

[255] Sherbenou DW,Forsberg P.Monoclonal antibodies in multiple myeloma: a new wave of the future..Clin Lymphoma Myeloma Leuk2017;17:545-54

[256] Maus MV.CARTs on the road for myeloma..Clin Cancer Res2014;20:3899-901 PMCID:PMC4119563

[257] Fernandez-Poma SM,Lozano T,Riezu-Boj JI,Elizalde E,Zubeldia N,Conde E,Lasarte JJ.Expansion of tumor-infiltrating CD8(+) T cells expressing PD-1 improves the efficacy of adoptive t-cell therapy..Cancer Res2017;77:3672-84

[258] Chu J,Benson DM,Hughes T,Peng Y,Yi L,He X,Zhang X,Hofmeister CC.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma..Leukemia2014;28:917-27 PMCID:PMC3967004

[259] Larocca A.Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach..J Clin Oncol2016;doi: 10.1200/JCO.2016.68.6113.

[260] Hari PN,Roy V,Bashey A,Elfenbein G,Gale RP,Kyle RA,McCarthy PL,Pavlovsky S,Schiller G,Weisdorf D.Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant..Leukemia2009;23:1528-34 PMCID:PMC2726276

[261] Kastritis E,Roussou M,Migkou M,Fotiou D,Panagiotidis I,Giannouli S,Konstantopoulos K.Evaluation of the revised international staging system in an independent cohort of unselected patients with multiple myeloma..Haematologica2017;102:593-9 PMCID:PMC5394955

[262] Agarwal MB.Multiple myeloma: treatment is getting individualized..Indian J Hematol Blood Transfus2016;32:3-9 PMCID:PMC4733675

[263] van Rhee F,Anaissie E,Waheed S,Petty N,Hoering A,Barlogie B.Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy..Blood2010;116:1220-7 PMCID:PMC2938233

[264] Keats JJ,Egan JB,Palmer SE,Van Wier S,Baker AS,Kumar S,Carpten JD,Fonseca R,Bergsagel PL.Clonal competition with alternating dominance in multiple myeloma..Blood2012;120:1067-76 PMCID:PMC3412330

[265] Sikic BI.Modulation of multidrug resistance: a paradigm for translational clinical research..Oncology (Williston Park).1999;13:183-7